Axonics Modulation Technologies Secures $32.6 Million in Series A Financing

Represented Irvine-based Axonics Modulation Technologies, Inc. in its $32.6 million Series A preferred stock financing. The financing was led by Edmond de Rothschild Investment Partners (EdRIP) and included NeoMed Management, Legend Capital, and a select group of private individuals.

Axonics is a privately held venture-backed pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.